These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1037 related items for PubMed ID: 17549359

  • 1. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS, Kim SW.
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [Abstract] [Full Text] [Related]

  • 2. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y.
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [Abstract] [Full Text] [Related]

  • 3. An immunohistochemical evaluation of phosphorylated Akt at threonine 308 [pAkt(Thr308)] in invasive breast cancer.
    Magkou C, Mylona E, Theohari I, Giannopoulou I, Papanikolaou E, Markaki S, Nakopoulou L.
    In Vivo; 2007 Mar; 21(6):967-72. PubMed ID: 18210742
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
    Anticancer Res; 2005 Mar; 25(3A):1719-23. PubMed ID: 16033090
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y.
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
    Park SS, Kim JE, Kim YA, Kim YC, Kim SW.
    Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
    [Abstract] [Full Text] [Related]

  • 10. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome.
    Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M, Winters ZE.
    Eur J Cancer; 2005 May; 41(7):1017-25. PubMed ID: 15862750
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
    Bebenek M, Bar JK, Harlozinska A, Sedlaczek P.
    Anticancer Res; 1998 May; 18(1B):619-23. PubMed ID: 9568187
    [Abstract] [Full Text] [Related]

  • 14. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients.
    Florena AM, Tripodo C, Guarnotta C, Ingrao S, Porcasi R, Martorana A, Lo Bosco G, Cabibi D, Franco V.
    Pathobiology; 2007 May; 74(6):317-22. PubMed ID: 18087195
    [Abstract] [Full Text] [Related]

  • 15. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [Abstract] [Full Text] [Related]

  • 16. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H, Nishio K, Ono M, Kuwano M, Kage M.
    Cancer Res; 2008 Mar 01; 68(5):1504-12. PubMed ID: 18316615
    [Abstract] [Full Text] [Related]

  • 17. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M.
    Breast Cancer Res Treat; 2006 Jun 01; 97(3):275-83. PubMed ID: 16344916
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep 01; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 19. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM.
    Oncol Rep; 2007 Jul 01; 18(1):121-6. PubMed ID: 17549356
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R, Potemski P, Jesionek-Kupnicka D, Kordek R.
    Pol J Pathol; 2005 Jul 01; 56(3):107-10. PubMed ID: 16334976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.